Sygnis AG (formerly Sygnis Pharma AG) plans to acquire TGR BioSciences Pty Ltd for €10.4m ($12.78m).

Sygnis will make an upfront payment of €6.5m ($7.98m), €1.3m ($1.59m) of promissory note loan, and €1.88m ($2.31m) of performance-related earn-out agreement or a convertible bond priced at €1.5 ($1.84), as part of the acquisition.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sygnis has concurrently issued 4.74 million new shares priced at €1.4 ($1.72) a share in a private placement to raise €6.64m ($8.16m).

Based in Germany, Sygnis is a biopharmaceutical company, while TGR is an Australian immunoassay technology company.

The acquisition will strengthen Sygnis’ technology portfolio and expand its customer base.

The funds managed under Apax Partners have signed a definitive agreement to purchase a stake in Vyaire Medical from US-based medical technology company Becton, Dickinson and Company (BD) for $435m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The acquisition will strengthen Sygnis’ technology portfolio and expand its customer base.”

Vyaire Medical will be completely controlled by the Apax Funds.

BD plans to use the proceeds for its broader capital allocation strategy.

Based in the UK, Apax Partners is a private equity firm, while Vyaire Medical is a US-based manufacturer of medical devices.

Platinum Equity LLC has announced the submission of a binding offer to acquire LifeScan Inc from medical devices and pharmaceuticals manufacturer Johnson and Johnson for $2.1bn.

Based in the US, Platinum Equity is a private equity firm, while LifeScan, also based in the US, is a manufacturer of blood glucose monitoring systems.

Thermo Fisher Scientific Inc has completed the acquisition of rapid DNA technology platform provider IntegenX Inc.

Thermo Fisher Scientific is a multi-national biotechnology product development company.

Both the companies involved in the transaction are based in the US.

The acquisition will enable Thermo Fisher to expand and develop its business in the human identification market.